ClinicalTrials.gg

Program

obicetrapib

Also written as “TA-8995”, “Obicetrapib” and “Obicetrapib 10 mg”.

Its studies are mostly in Dyslipidemias · Hypercholesterolemia · Alzheimer Disease · Hyperlipidemias · Atherosclerosis, led by 3 companies.

Furthest: phase 3, since Nov 18, 202127 company-led studies, 7 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
NewAmsterdam Pharma197 open or runningphase 3since Nov 18, 2021Feb 9, 2021Nov 2026phase 2 · NCT06496243
Xention60 open or runningphase 2since Oct 21, 2013Oct 21, 2013none ahead
Tanabe Pharma20 open or runningphase 1since Jun 4, 2013Jun 4, 2013none ahead

Also a collaborator on its studies: pharma-medica-research-inc and novum.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 13 studies since Jun 4, 2013.

  1. Feb 23, 2022Phase 2 study in DyslipidemiasNewAmsterdam Pharma · NCT05266586 · 119 enrolled · United States
  2. Jun 13, 2022Phase 2 study in DyslipidemiasNewAmsterdam Pharma · NCT05421078 · 102 enrolled · Japan
  3. Jun 15, 2022Phase 3 study in DyslipidemiasNewAmsterdam Pharma · NCT05425745 · 354 enrolled · United States, Canada, Czechia and more
  4. Jul 25, 2023Phase 1 study in Lipid MetabolismNewAmsterdam Pharma · NCT05972278 · 22 enrolled · United States
  5. Aug 15, 2023Phase 3 study in DyslipidemiasNewAmsterdam Pharma · NCT06005597 · 407 enrolled · United States
  6. Aug 29, 2023Phase 1 study in Hepatic ImpairmentNewAmsterdam Pharma · NCT06048302 · 18 enrolled · United States
  7. Oct 3, 2023Phase 1 study in Healthy VolunteersNewAmsterdam Pharma · NCT06081166 · 74 enrolled · Canada
  8. Feb 1, 2024Phase 1 study in Healthy VolunteersNewAmsterdam Pharma · NCT06250205 · 30 enrolled · United States
  9. Feb 28, 2024Phase 3 study in HyperlipidemiasNewAmsterdam Pharma · NCT06305559 · 300 enrolled · United States
  10. Jul 3, 2024Phase 2 study in DyslipidemiasNewAmsterdam Pharma · NCT06496243 · 69 planned · United States
  11. Aug 1, 2024Phase 1 study in Healthy VolunteersNewAmsterdam Pharma · NCT06547359 · 94 enrolled · Canada
  12. May 13, 2025Phase 2 study in Antioxidant AbsorptionNewAmsterdam Pharma · NCT06982508 · 100 planned · United States
  13. Oct 20, 2025Phase 3 study in HyperlipidemiasNewAmsterdam Pharma · NCT07219602 · 300 enrolled · United States, Czechia, Netherlands and more
  14. Aug 12, 2026Phase 2 study in Alzheimer DiseaseNewAmsterdam Pharma · NCT07794670 · 400 planned · United States

Ahead

  1. Nov 2026Primary completion: phase 2 study in DyslipidemiasNewAmsterdam Pharma · NCT06496243
  2. Nov 2026Primary completion: phase 3 study in AtherosclerosisNewAmsterdam Pharma · NCT05202509
  3. Nov 2027Primary completion: phase 3 study in HyperlipidemiasNewAmsterdam Pharma · NCT06305559
  4. Mar 2028Primary completion: phase 3 study in HyperlipidemiasNewAmsterdam Pharma · NCT07219602

TargetBeta

CETP →read by rule
“Cholesteryl ester transfer protein inhibitor”ChEMBL 37, by rule

Studies

All 27 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07794670Alzheimer Disease · United States2RecruitingNewAmsterdam PharmaSep 2028400
NCT07219602Hyperlipidemias · United States, Czechia, Netherlands and more3Active, not recruitingNewAmsterdam PharmaMar 2028300
NCT06982508Antioxidant Absorption · United States2RecruitingNewAmsterdam PharmaSep 2026100
NCT06547359Healthy Volunteers · Canada1CompletedNewAmsterdam PharmaNov 12, 202494
NCT06496243Dyslipidemias · United States2RecruitingNewAmsterdam PharmaNov 202669
NCT06305559Hyperlipidemias · United States3Active, not recruitingNewAmsterdam PharmaNov 2027300
NCT06250205Healthy Volunteers · United States1CompletedNewAmsterdam PharmaApr 25, 202430
NCT06081166Healthy Volunteers · Canada1CompletedNewAmsterdam PharmaDec 2, 202374
NCT06048302Hepatic Impairment · United States1CompletedNewAmsterdam PharmaMar 12, 202418
NCT06005597Dyslipidemias · United States3CompletedNewAmsterdam PharmaSep 25, 2024407
NCT05972278Lipid Metabolism · United States1Active, not recruitingNewAmsterdam PharmaSep 26, 202422
NCT05425745Dyslipidemias · United States, Canada, Czechia and more3CompletedNewAmsterdam PharmaMay 28, 2024354
NCT05421078Dyslipidemias · Japan2CompletedNewAmsterdam PharmaMar 24, 2023102
NCT05266586Dyslipidemias · United States2CompletedNewAmsterdam PharmaAug 12, 2022119
NCT05161715Alzheimer Disease · Netherlands2CompletedNewAmsterdam PharmaMay 9, 202313
NCT05202509Atherosclerosis · United States, Australia, Bulgaria and more3Active, not recruitingNewAmsterdam PharmaNov 20269,541
NCT05142722Dyslipidemias · United States, China, Czechia and more3CompletedNewAmsterdam PharmaSep 26, 20242,530
NCT04770389Dyslipidemias · United States, Netherlands2CompletedNewAmsterdam PharmaMay 7, 2021112
NCT04753606Dyslipidemias · United States2CompletedNewAmsterdam PharmaMay 24, 2021120
NCT02523391Dyslipidemias · United Kingdom1CompletedXentionNov 201526
NCT02408055Dyslipidemias · United Kingdom1CompletedXentionAug 20156
NCT02241772Elevated Lp(a) · Denmark2CompletedXentionJan 201542
NCT02241759Dyslipidemias · United Kingdom1CompletedXentionNov 2014136
NCT02124954Pharmacokinetic Interactions · United Kingdom1CompletedXentionJul 201418
NCT01970215Dyslipidemias · Denmark, Netherlands2CompletedXentionJul 2014364
NCT01879020Dyslipidemias · Germany1CompletedTanabe PharmaJun 201061
NCT01878474Dyslipidemias · United Kingdom1CompletedTanabe PharmaJun 200996

How it is read

Names in the registry

  • “TA-8995”, 16 entries
  • “Obicetrapib”, 11 entries
  • “Obicetrapib 10 mg”, 2 entries
  • “obicetrapib 10 mg + ezetimibe 10 mg FDC daily”, 2 entries
  • “Obicetrapib 10mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.